Sign up for a free trial now
  • Login
  • Subscribe
  • Take a FREE Trial
  • About Us
  • Contact us
  • RSS

25 May 2013


The Pharma Letter
  • Home
  • 7 Day Premium Trial
  • Pharmaceuticals
  • Biotechnology
  • Generics
  • Events
  • Companies
  • Drugs
  • Subscribe

Betaxolol Hydrochloride Articles

Three blockbusters continue to drive Sanofi-Synthelabo sales growth

28 January 2002

Sanofi-Synthelabo sales push $1.3 billion

26 April 2000

Sanofi-Synthelabo's three blockbusters push 1999 sales to 5.35 billion euros

27 January 2000

Sanofi-Synthelabo sales up 9% in 3rd quarter

1 November 1999

Sanofi-Synthelabo 1st-half profits up 18%

1 September 1999

Synthelabo full-year sales increase 7.1%

19 January 1999

Synthelabo Predicts Strong Opportunities For Growth

6 April 1998

Sales at Synthelabo Grow 12.7% in 1994

6 February 1995

Overseas Sales Lift Synthelabo Nine Month Results

14 November 1994

ANANXYL WITHDRAWN FROM MARKET IN FRANCE

1 November 1993

SYNTHELABO EXPECTS 23% RISE IN '93 PROFITS

25 October 1993

SYNTHELABO TAKES ON EUROPEAN DIMENSION

26 July 1993

SYNTHELABO'S SALES ALMOST DOUBLE IN 1992

12 April 1993

Synthelabo's Product Portfolio

25 May 1992

ELI LILLY BUYS STAKE IN BEIERSDORF GmbH

27 April 1992

Showing 1-15 of 15 articles

Go to beginningPrevious
  • 1
NextGo to end
  • Hot Topics
  • Most Read
  • Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
  • Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
  • Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
  • Proposal to list Roche's Neulastim and Actemra in New Zealand
  • Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
  • Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
  • Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
  • Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
  • Proposal to list Roche's Neulastim and Actemra in New Zealand
  • Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth

30 Day Premium Trial


Events

Twitter Right banner

RSS



© 2013 thepharmaletter.com

  • Home
  • RSS
  • About Us
  • Subscribe
  • Terms and Conditions
  • Article Archive
Site powered by WORKSsitebuilder CMS